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Atrial fibrillation (AF) is the most common
sustained arrhythmia [1]. It affects an estimated
2 million people in the United States alone, and
accounts for over 70,000 cerebrovascular events
yearly. With an aging population, the incidence of
AF is expected to rise dramatically over the next
2 decades. In addition, two thirds of patients with
congestive heart failure (CHF) have AF [2]. These
two disease states are closely interrelated, as CHF
may promote the development of AF and vice ver-
sa. AF is also a marker for increased mortality in
patients with LV dysfunction [3].
Atrial fibrillation may potentially worsen CHF
by multiple mechanisms, including a direct increase
in chronotropy and decrease in filling time; along with
a loss of the atrial contribution to filling. Indirectly,
there may be adverse effects via the negative ino-
tropic and proarrhythmic effects from medications
used to treat AF. Persistent AF may therefore con-
tribute to both LV systolic and diastolic dysfunction
in patients.
Several large trials (e.g, AFFIRM, RACE,
HOT-CAFÉ) that randomized patients to rhythm
versus rate control strategies in AF were recently
published [4, 5]. The largest of such trials, the
AFFIRM trial, found no survival or events benefit
between the two groups. Similarly in a substudy,
no differences in functional class (deterioration)
over time or mini-mental status examinations were
demonstrated (although a small increase in 6 minute
walk test duration was noted to be statistically signi-
ficant) [6]. An additional prespecified Quality of Life
(QOL) substudy of AFFIRM revealed no difference
in QOL between the rhythm versus rate control arms;
nor was there a difference between those in sinus
rhythm versus those in persistent atrial fibrillation (re-
gardless of randomization treatment group) [7].
As pointed out in the current paper by Szulc et
al, no large study to date has looked at the impor-
tant question of serial LV function in a population
of AF patients randomized to rate vs. rhythm con-
trol. The majority of patients with baseline echo-
cardiographic data in AFFIRM had normal left ven-
tricular ejection fraction (LVEF) at enrollment.
However, there was no serial assessment of LV
function over time. This leads us to the important
question asked in the study of Szulc et al. in a sub-
set of the HOT-CAFÉ trial population of patients:
what is the effect of rate versus rhythm control on
left ventricular function over time?
In this study, patients with a mean age of
61 years and with persistent AF were randomized
to rate control versus rhythm control with DC car-
dioversion and/or antiarrhythmic medication. After
12 months of follow up, 64% of patients (in the rhy-
thm control group) were deemed to be in sinus rhy-
thm. This, once again, emphasizes the difficulty
with attaining and maintaining sinus rhythm over
time with conventional treatment. It may also be of
importance to note that 21% of the enrolled patients
had lone AF and 90% were class I and II NYHA func-
tional class. Thus, this was a relatively young and
healthy population at baseline.
Mean left ventricular echocardiographic para-
meters, which included left ventricular end-diasto-
lic (LVEDD) and systolic dimensions (LVESD) as
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well as fractional shortening (FS), were within
normal limits at baseline; indicating further that this
cohort was comprised predominantly of those with
AF and normal left ventricular systolic function. The
conclusion in this study was that LV morphology
and LV systolic function (as assessed by LVEDD,
LVESD and FS) were not significantly different
after 12 months of follow up, irrespective of rate vs.
rhythm control treatment strategy.
In their discussion, the authors accurately
point out that the “baseline systolic function in the
overall study group was relatively preserved”. Also,
they state that their population “seemed to be well
representative for the average population of pa-
tients with AF”. Their findings would seem to cor-
relate with the findings of the large, randomized
trials of rate vs. rhythm control. In these trials,
there was no advantage amongst treatment groups
in survival or event rates; nor was their any appre-
ciable difference in QOL or functional class. Thus,
one might expect that LV function would not signi-
ficantly deteriorate in one treatment group versus
the other. However, can these results be extrapo-
lated to a more complex population of patients with
significant LV dysfunction at baseline?
A recent French study examining rhythm
control in AF (via circumferential pulmonary vein
ablation) in patients with significantly reduced
LVEF (average LVEF 35 ± 7%) demonstrated signi-
ficant improvement in LV function, with a 21 ± 13%
increase in LVEF and an 11 ± 7% increase in
fractional shortening in those patients who had ba-
seline LV dysfunction [8]. Further, patients with
poor rate control pre-ablation had superior impro-
vements in LV function, compared to those with
adequate rate control pre-ablation. Whether this
benefit in LV function can be generalized to a sub-
set of the population of patients in the large rando-
mized trials of rate vs. rhythm control is currently
unclear. For example, follow-up echocardiograms
were not mandated in AFFIRM, and therefore the
data is lacking [9].
And, as noted, patients selected for the study
by Szulc et al. were a generally younger and heal-
thier cohort with predominantly normal LV systolic
function at baseline, in comparison to those recru-
ited for previous rate versus rhythm control trials.
In this relatively select population, the primary end-
point (of LV morphology and function) failed to im-
prove significantly in either treatment group.
Given the stated limitations in this well-orga-
nized study of Szulc et al, both the HOT CAFÉ trial
and this substudy add to the overall knowledge base
in AF. However, the ongoing controversy remains
relative to the fundamental question: is it better to
attain sinus rhythm or leave the patient in AF and
control the rate? In our humble opinion, the studies
to date were not designed to answer this fundamen-
tal question. Rather these studies determined that,
with the current means at hand (including the rela-
tive ineffectiveness of conventional antiarrythmic
agents, with high recurrence rates of AF and the
potential side-effects) that rhythm control offers no
advantage over rate control in the population of AF
patients tested.
Further research needs to be performed in or-
der to elucidate whether patients with depressed
LV function and AF have improvement in survival,
events, QOL, functional class and/or LV function
with strategies of rate versus rhythm control. Also,
it needs to be determined whether improved me-
thods of attainment and maintenance of sinus rhy-
thm can demonstrate a genuine advantage with rhy-
thm control. Ongoing randomized trials, such as the
Atrial Fibrillation and Congestive Heart Failure
(AF-CHF) trial, will attempt to answer some of the-
se questions [10].
Finally, in a cost-effective world, searching for
accurate surrogate endpoints (which occur earlier,
with higher frequency, and which accurately pre-
dict the hard endpoint of interest) may prove to be
very beneficial. If true surrogate endpoints can be
defined, some of these important questions may be
answered without the repeated cost of very large
clinical trials [11].
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